{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360574095380320896.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1185/03007995.2011.580341"}},{"identifier":{"@type":"URI","@value":"https://www.tandfonline.com/doi/pdf/10.1185/03007995.2011.580341"}},{"identifier":{"@type":"PMID","@value":"21554143"}}],"dc:title":[{"@value":"Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02"}],"description":[{"notation":[{"@value":"The authors conducted a randomized controlled trial to clarify the efficacy and safety of alendronate plus alfacalcidol versus alendronate alone in a clinical setting.Eligible patients were postmenopausal women with severe osteoporosis who were aged 70 years or older and had several risk factors for incident fractures. The primary endpoint was prevention of incident fractures, and the anti-fracture efficacy was evaluated in relation to the baseline serum 25(OH)D level.A total of 2164 patients were randomized to alendronate plus alfacalcidol (combination therapy) or alendronate alone (monotherapy). Although the overall difference in the incidence of vertebral fracture between the two groups was not significant, the combination therapy group had a significantly reduced risk of vertebral fractures after the first 6 months (HR, 0.53). In subgroup analyses, the combination therapy group was superior in the strata of number of prevalent vertebral fractures of ≥2 (HR, 0.51) and grade 3 of prevalent vertebral fractures (HR, 0.55). The rate of non-vertebral weight-bearing bone fractures was significantly lower in the combination therapy group than in the monotherapy group during the follow-up period (HR, 0.31). A lower baseline 25(OH)D level was associated with a higher incidence of non-vertebral weight-bearing bone fractures (HR, 3.42) despite alendronate use. Although one patient given the combination therapy had mild hypercalcemia, serious hypercalcemia and unknown adverse events were not encountered. Because of the limitations presented in this study, these results may not apply to female patients with longer than 2 years of treatments, and to male osteoporosis patients.The combination therapy was no more effective for overall vertebral fracture prevention. However, subgroup analysis has shown that it was more effective for fracture prevention in patients with severe vertebral deformity, multiple prevalent vertebral fractures, and for non-vertebral weight-bearing bone fracture prevention."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380574095380320771","@type":"Researcher","foaf:name":[{"@value":"Hajime Orimo"}],"jpcoar:affiliationName":[{"@value":"Health Science University,\rYamanashi, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320900","@type":"Researcher","foaf:name":[{"@value":"Masao Fukunaga"}],"jpcoar:affiliationName":[{"@value":"Department of Nuclear Medicine, Kawasaki Medical School,\rOkayama, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320897","@type":"Researcher","foaf:name":[{"@value":"Toshitaka Nakamura"}],"jpcoar:affiliationName":[{"@value":"Department of Orthopedic Surgery, University of Occupational and Environmental Health School of Medicine,\rFukuoka, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320898","@type":"Researcher","foaf:name":[{"@value":"Hiroaki Ohta"}],"jpcoar:affiliationName":[{"@value":"Department of Obstetric and Gynecology, Tokyo Women’s Medical University,\rTokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320770","@type":"Researcher","foaf:name":[{"@value":"Takayuki Hosoi"}],"jpcoar:affiliationName":[{"@value":"Department of Clinical Research and Development, National Center for Geriatrics and Gerontology,\rAichi, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320768","@type":"Researcher","foaf:name":[{"@value":"Tatsuhiko Kuroda"}],"jpcoar:affiliationName":[{"@value":"Public Health Research Foundation,\rTokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276189698560","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"80548537"},{"@type":"NRID","@value":"1000080548537"},{"@type":"NRID","@value":"9000259322241"},{"@type":"NRID","@value":"9000394955087"},{"@type":"NRID","@value":"9000238225147"},{"@type":"NRID","@value":"9000396162823"},{"@type":"NRID","@value":"9000415412816"},{"@type":"NRID","@value":"9000399361905"},{"@type":"NRID","@value":"9000401506153"},{"@type":"NRID","@value":"9000404537343"},{"@type":"NRID","@value":"9000377395257"},{"@type":"NRID","@value":"9000257999190"},{"@type":"NRID","@value":"9000388456476"},{"@type":"NRID","@value":"9000409789055"},{"@type":"NRID","@value":"9000398458014"},{"@type":"NRID","@value":"9000411393582"},{"@type":"NRID","@value":"9000314067157"},{"@type":"NRID","@value":"9000402395099"},{"@type":"NRID","@value":"9000399255128"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/yuemura"}],"foaf:name":[{"@value":"Yukari Uemura"}],"jpcoar:affiliationName":[{"@value":"Department of Biostatistics, School of Public Health, The University of Tokyo,\rTokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320901","@type":"Researcher","foaf:name":[{"@value":"Nobuaki Miyakawa"}],"jpcoar:affiliationName":[{"@value":"Public Health Research Foundation,\rTokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320896","@type":"Researcher","foaf:name":[{"@value":"Yasuo Ohashi"}],"jpcoar:affiliationName":[{"@value":"Department of Biostatistics, School of Public Health, The University of Tokyo,\rTokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574095380320769","@type":"Researcher","foaf:name":[{"@value":"Masataka Shiraki"}],"jpcoar:affiliationName":[{"@value":"Department of Internal Medicine, Research Institute and Practice for Involutional Diseases,\rNagano, Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03007995"},{"@type":"EISSN","@value":"14734877"}],"prism:publicationName":[{"@value":"Current Medical Research and Opinion"}],"dc:publisher":[{"@value":"Informa Healthcare"}],"prism:publicationDate":"2011-05-10","prism:volume":"27","prism:number":"6","prism:startingPage":"1273","prism:endingPage":"1284"},"reviewed":"false","url":[{"@id":"https://www.tandfonline.com/doi/pdf/10.1185/03007995.2011.580341"}],"createdAt":"2011-05-10","modifiedAt":"2018-02-07","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Fractures,%20Bone","dc:title":"Fractures, Bone"},{"@id":"https://cir.nii.ac.jp/all?q=Alendronate","dc:title":"Alendronate"},{"@id":"https://cir.nii.ac.jp/all?q=Bone%20Density%20Conservation%20Agents","dc:title":"Bone Density Conservation Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Hydroxycholecalciferols","dc:title":"Hydroxycholecalciferols"},{"@id":"https://cir.nii.ac.jp/all?q=Osteoporosis","dc:title":"Osteoporosis"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360290617631708800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168919542656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis – monthly (four weeks) intravenous versus once weekly oral administrations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181232467712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656208883968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum 25-hydroxyvitamin D below 25 ng/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848659183518080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The increase in bone mineral density by bisphosphonate with active vitamin D analog is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361975839364832512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Simple methods for the estimation and sensitivity analysis of principal strata effects using marginal structural models: Application to a bone fracture prevention trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204242669952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204244122368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205024172672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A man is as old as his bones"},{"@language":"ja","@value":"ヒトは骨と共に老いる"},{"@value":"特別講演 ヒトは骨と共に老いる"},{"@language":"ja-Kana","@value":"トクベツ コウエン ヒト ワ ホネ ト トモニ オイル"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681423849856","@type":"Article","resourceType":"other","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"1. Progress in the Treatment of Osteoporosis"},{"@language":"ja","@value":"1．骨粗鬆症治療の進歩"},{"@value":"教育講演 骨粗鬆症治療の進歩"},{"@language":"ja-Kana","@value":"キョウイク コウエン コツソショウショウ チリョウ ノ シンポ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1185/03007995.2011.580341"},{"@type":"OPENAIRE","@value":"doi_dedup___::1cf550ed715f067f44f55bae55386473"},{"@type":"CROSSREF","@value":"10.1620/tjem.241.319_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.1620/tjem.237.339_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.2169/naika.101.2636_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.1080/03007995.2020.1816537_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.1007/s00774-018-0942-z_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.1007/s00774-013-0520-3_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.1080/14397595.2018.1442671_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.3143/geriatrics.50.16_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.1002/bimj.201800038_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"},{"@type":"CROSSREF","@value":"10.1185/03007995.2012.709838_references_DOI_216mAltTbWRJ34c81lzl1IxboSl"}]}